Overview

Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)

Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II, multicenter, open-label, imaging study of hCRF in the reduction of PBE in patients with primary malignant or metastatic brain tumors. Approximately 30 to 60 patients will be assigned to 1 of 3 treatment groups and receive study drug for up to 28 days
Phase:
Phase 2
Details
Lead Sponsor:
PharmaNet
Collaborator:
Celtic Pharma Development Services
Treatments:
Corticotropin-Releasing Hormone